Focus: Delcath is a specialty pharmaceutical company focused on developing innovative hepatic delivery systems and oncology treatments, with a public market presence trading under DCTH. The company operates at mid-cap scale (1,001–5,000 employees) from Queensbury, NY.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Delcath to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Delcath
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Delcath's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Recent NDA approval driving 18.5x revenue growth; company's sole marketed product with 9-year patent protection.
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - Earnings Season Outlook - newsline.com
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - Earnings Season Outlook newsline.com
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - Earnings Quality Analysis - The Legal Advocate
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - Earnings Quality Analysis The Legal Advocate
Liver melanoma trials test HEPZATO with systemic treatments at ASCO 2026 - Stock Titan
Liver melanoma trials test HEPZATO with systemic treatments at ASCO 2026 Stock Titan
8-K Filing: Profound Medical Corp. (PROF) (CIK 0001628808) — EXHIBIT 99.1
EXHIBIT 99.1
A liver-targeted breast cancer procedure drew new data at ESMO - Stock Titan
A liver-targeted breast cancer procedure drew new data at ESMO Stock Titan
Delcath Systems (NASDAQ: DCTH) grows Q1 2026 sales but posts small loss - Stock Titan
Delcath Systems (NASDAQ: DCTH) grows Q1 2026 sales but posts small loss Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.
Response to Letter to the Editor Regarding: An Open-Label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo